Research programme: anti-angiogenesis antibodies - Bionomics/Genmab
Latest Information Update: 30 Dec 2024
Price :
$50 *
At a glance
- Originator Bionomics; Genmab
- Class Antibodies
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 23 Dec 2024 Bionomics re-domiciled from Australia to USA and became wholly owned subsidiary of Neuphoria Therapeutics
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Australia (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Denmark (Parenteral)